Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial (Q33375139)

26 July 2017

title

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

Alexander Claviez

6

0 references

author name string

Thorsten Simon

1

1 reference

26 July 2017

Alfred Längler

2

1 reference

26 July 2017

Urs Harnischmacher

3

1 reference

26 July 2017

Michael C Frühwald

4

1 reference

26 July 2017

Norbert Jorch

5

1 reference

26 July 2017

Frank Berthold

7

1 reference

26 July 2017

Barbara Hero

8

1 reference

26 July 2017

publication date

4 May 2007

1 reference

Journal of Cancer Research and Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

133

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

653-661

1 reference

Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00432-007-0216-Y

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00432-007-0216-Y

A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00432-007-0216-Y

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

21 January 2018

1 reference

12 December 2020

DNA-topoisomerase I, a new target for the treatment of neuroblastoma

1 reference

12 December 2020

OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

1 reference

12 December 2020

Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide

1 reference

12 December 2020

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

1 reference

12 December 2020

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

1 reference

12 December 2020

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

1 reference

12 December 2020

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

12 December 2020

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis

1 reference

12 December 2020

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan

1 reference

12 December 2020

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma

1 reference

12 December 2020

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study

1 reference

12 December 2020

Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age.

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

12 December 2020

Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response

1 reference

12 December 2020

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

12 December 2020

Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

1 reference

12 December 2020

Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma Xenografts

1 reference

12 December 2020

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

1 reference

12 December 2020

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors

1 reference

12 December 2020

Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study

1 reference

12 December 2020

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

12 December 2020

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

12 December 2020

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide

1 reference

12 December 2020

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study

1 reference

12 December 2020

Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

1 reference

12 December 2020

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

1 reference

12 December 2020

A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients

1 reference

12 December 2020

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.

1 reference

12 December 2020

DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors

1 reference

12 December 2020

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

12 December 2020

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

12 December 2020

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study

1 reference

12 December 2020

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach

1 reference

12 December 2020

Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines

1 reference

12 December 2020

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process

1 reference

12 December 2020

The significance of the sequence of administration of topotecan and etoposide

1 reference

12 December 2020

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

1 reference

12 December 2020

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

1 reference

12 December 2020

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer

1 reference

12 December 2020

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

12 December 2020

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines

1 reference

12 December 2020

10.1007/S00432-007-0216-Y

Identifiers

DOI

1 reference

26 July 2017

1 reference